Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $118.40 million for the quarter. Zai Lab has set its FY 2025 guidance at EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Trading Up 0.1 %

ZLAB stock traded up $0.03 during trading on Friday, hitting $31.18. 727,164 shares of the company's stock were exchanged, compared to its average volume of 860,627. The business has a 50-day moving average price of $33.20 and a two-hundred day moving average price of $29.73. The stock has a market capitalization of $3.43 billion, a price-to-earnings ratio of -11.26 and a beta of 1.04. Zai Lab has a 52-week low of $16.01 and a 52-week high of $39.77.

Insiders Place Their Bets

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the business's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $17,032,212.99. The trade was a 9.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Frazor Titus Edmondson III sold 14,544 shares of the firm's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $32.98, for a total value of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares of the company's stock, valued at approximately $472,537.44. This represents a 50.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 138,744 shares of company stock worth $4,685,294. 13.88% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on ZLAB. Scotiabank began coverage on Zai Lab in a research note on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price objective for the company. JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Bank of America reiterated a "neutral" rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a research report on Thursday, March 27th.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.